Pep2Dia is an innovative bioactive that delays the onset of type 2 diabetes

Published: 22-Oct-2019

Ingredia will be at CPhI in 2019 with its new bioactive, a patented milk protein hydrolysate with an active dipeptide AP, specifically designed for prediabetes

Pep2Dia is a patented1 milk protein hydrolysate with an active dipeptide AP, specifically designed for prediabetes, to help manage blood sugar. AP peptide acts as an inhibitor of the alpha glucosidase. This digestive enzyme hydrolyses polysaccharides into glucose and allows absorption. Its inhibition lowers blood sugar levels.

Pep2Dia is the result of extensive research and collaboration between Ingredia's scientists and LIENSs-CNRS La Rochelle University in France.

Pep2Dia has proven efficacy on glycaemia after meals

Pre-clinical and clinical studies support Pep2Dia's action to reduce postprandial glycaemia with a significative effect versus the placebo.

Diabetes, a world public health concern

Today more than 350 million people live with high blood sugar glucose2. In 5 to 10 years, if nothing is done, the people with prediabetes, who have a higher-than-normal glycaemia in the morning fasting, will become diabetic. Everywhere, diabetes is on the rise and affects 8.5% of the adult population3.

Diabetes leads to adverse effects on health, and in the long run can affect eyes, kidneys, feet, cause heart conditions or stroke. This chronic disease is one of the causes of premature moratality but type 2 diabetes can be avoided because prediabetes is reversible!

To prevent Type 2 diabetes change your food habits, exercise and take ... Pep2Dia!

Ingredia will be at CPhI this year at stand 40K49.

  1. Patent n° WO 2015/124867
  2. International Diabetes Fundation, Atlas 2018
  3. WHO Global report on diabetes, 2016

You may also like